| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 |
| filingDate |
2008-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b368858c5067bace51693a9557a5dc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ffde7894e76ad478f3cb2c489ffef29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9503052ab957cf36c05c31e46422a071 |
| publicationDate |
2015-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2563808-C2 |
| titleOfInvention |
Modified capsular saccharide, method for production and use thereof |
| abstract |
FIELD: chemistry. n SUBSTANCE: group of inventions relates to biotechnology. The invention discloses a modified capsular saccharide for inducing humoral immune response, a method for production and use thereof in preventing or treating bacterial meningitis, a saccharide-protein conjugate and methods for production thereof, a pharmaceutical composition based on the modified capsular saccharide and a method of inducing humoral immune response in mammals. The modified capsular saccharide contains a blocking group in the hydroxyl group position on at least 80% of monosaccharide units of the corresponding native capsular saccharide. The blocking group has the formula (Ia): -O-X-Y (Ia), where X is C(O); Y is C 1-6 alkyl, substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amino groups. n EFFECT: disclosed modified capsular saccharide is more resistant to hydrolysis than the native saccharide; presence of said blocking group provides more effective conjugation of the modified capsular saccharide with a carrier molecule. n 38 cl, 9 dwg, 4 tbl, 2 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2789546-C2 |
| priorityDate |
2007-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |